These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 9764962)
21. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Nordberg A; Svensson AL Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of tacrine hydrochloride in Alzheimer's disease. Forsyth DR; Wilcock GK; Morgan RA; Truman CA; Ford JM; Roberts CJ Clin Pharmacol Ther; 1989 Dec; 46(6):634-41. PubMed ID: 2598567 [TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats. Goh CW; Aw CC; Lee JH; Chen CP; Browne ER Drug Metab Dispos; 2011 Mar; 39(3):402-11. PubMed ID: 21148081 [TBL] [Abstract][Full Text] [Related]
24. Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine. Amchin J; Zarycranski W; Taylor KP; Albano D; Klockowski PM J Clin Pharmacol; 1999 Mar; 39(3):252-9. PubMed ID: 10073324 [TBL] [Abstract][Full Text] [Related]
25. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Faber MS; Jetter A; Fuhr U Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):125-34. PubMed ID: 16128905 [TBL] [Abstract][Full Text] [Related]
26. Caffeine metabolism in a group of 67 patients with primary biliary cirrhosis. Lelouët H; Bechtel YC; Paintaud G; Brientini MP; Miguet JP; Bechtel PR Int J Clin Pharmacol Ther; 2001 Jan; 39(1):25-32. PubMed ID: 11204934 [TBL] [Abstract][Full Text] [Related]
27. Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity. Terziivanov D; Bozhinova K; Dimitrova V; Atanasova I Clin Pharmacokinet; 2003; 42(15):1393-409. PubMed ID: 14674790 [TBL] [Abstract][Full Text] [Related]
28. Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance. Spigset O; Hägg S; Söderström E; Dahlqvist R Eur J Clin Pharmacol; 1999 Feb; 54(12):943-6. PubMed ID: 10192755 [TBL] [Abstract][Full Text] [Related]
29. Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2? De Kesel PM; Lambert WE; Stove CP Clin Pharmacokinet; 2015 Jul; 54(7):771-81. PubMed ID: 25603821 [TBL] [Abstract][Full Text] [Related]
31. Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans. Bapiro TE; Sayi J; Hasler JA; Jande M; Rimoy G; Masselle A; Masimirembwa CM Eur J Clin Pharmacol; 2005 Nov; 61(10):755-61. PubMed ID: 16261361 [TBL] [Abstract][Full Text] [Related]
32. Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe. Spaldin V; Madden S; Adams DA; Edwards RJ; Davies DS; Park BK Drug Metab Dispos; 1995 Sep; 23(9):929-34. PubMed ID: 8565783 [TBL] [Abstract][Full Text] [Related]
33. Pantoprazole lacks induction of CYP1A2 activity in man. Hartmann M; Zech K; Bliesath H; Steinijans VW; Koch H; Wurst W; Mascher H Int J Clin Pharmacol Ther; 1999 Apr; 37(4):159-64. PubMed ID: 10235417 [TBL] [Abstract][Full Text] [Related]
34. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577 [TBL] [Abstract][Full Text] [Related]
35. Bioavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease. Lou G; Montgomery PR; Sitar DS J Psychiatry Neurosci; 1996 Nov; 21(5):334-9. PubMed ID: 8973053 [TBL] [Abstract][Full Text] [Related]
36. Salivary clearance and urinary metabolic pattern of caffeine in healthy children and in pediatric patients with hepatocellular diseases. el-Yazigi A; Shabib S; al-Rawithi S; Yusuf A; Legayada ES; al-Humidan A J Clin Pharmacol; 1999 Apr; 39(4):366-72. PubMed ID: 10197295 [TBL] [Abstract][Full Text] [Related]
37. Multifunctional tacrine-trolox hybrids for the treatment of Alzheimer's disease with cholinergic, antioxidant, neuroprotective and hepatoprotective properties. Xie SS; Lan JS; Wang XB; Jiang N; Dong G; Li ZR; Wang KD; Guo PP; Kong LY Eur J Med Chem; 2015 Mar; 93():42-50. PubMed ID: 25656088 [TBL] [Abstract][Full Text] [Related]
38. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Shirley KL; Hon YY; Penzak SR; Lam YW; Spratlin V; Jann MW Neuropsychopharmacology; 2003 May; 28(5):961-6. PubMed ID: 12644842 [TBL] [Abstract][Full Text] [Related]
39. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Becquemont L; Ragueneau I; Le Bot MA; Riche C; Funck-Brentano C; Jaillon P Clin Pharmacol Ther; 1997 Jun; 61(6):619-27. PubMed ID: 9209244 [TBL] [Abstract][Full Text] [Related]
40. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Rostami-Hodjegan A; Nurminen S; Jackson PR; Tucker GT Pharmacogenetics; 1996 Apr; 6(2):121-49. PubMed ID: 9156692 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]